Literature DB >> 20093366

Energy restriction as an antitumor target of thiazolidinediones.

Shuo Wei1, Samuel K Kulp, Ching-Shih Chen.   

Abstract

Cancer cells gain growth advantages in the microenvironment by shifting cellular metabolism to aerobic glycolysis, the so-called Warburg effect. There is a growing interest in targeting aerobic glycolysis for cancer therapy by exploiting the differential susceptibility of malignant versus normal cells to glycolytic inhibition, of which the proof-of-concept is provided by the in vivo efficacy of dietary caloric restriction and natural product-based energy restriction-mimetic agents (ERMAs) such as resveratrol and 2-deoxyglucose in suppressing carcinogenesis in animal models. Here, we identified thiazolidinediones as a novel class of ERMAs in that they elicited hallmark cellular responses characteristic of energy restriction, including transient induction of Sirt1 (silent information regulator 1) expression, activation of the intracellular fuel sensor AMP-activated protein kinase, and endoplasmic reticulum stress, the interplay among which culminated in autophagic and apoptotic death. The translational implications of this finding are multifold. First, the novel function of troglitazone and ciglitazone in targeting energy restriction provides a mechanistic basis to account for their peroxisome proliferator-activated receptor gamma-independent effects on a broad spectrum of signaling targets. Second, we demonstrated that Sirt1-mediated up-regulation of beta-transducin repeat-containing protein-facilitated proteolysis of cell cycle- and apoptosis-regulatory proteins is an energy restriction-elicited signaling event and is critical for the antitumor effects of ERMAs. Third, it provides a molecular rationale for using thiazolidinediones as scaffolds to develop potent ERMAs, of which the proof-of-principle is demonstrated by OSU-CG12. OSU-CG12, a peroxisome proliferator-activated receptor gamma-inactive ciglitazone derivative, exhibits 1- and 3-order of magnitude higher potency in eliciting starvation-like cellular responses relative to resveratrol and 2-deoxyglucose, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093366      PMCID: PMC2843227          DOI: 10.1074/jbc.M109.065466

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.

Authors:  Y Kabeya; N Mizushima; T Ueno; A Yamamoto; T Kirisako; T Noda; E Kominami; Y Ohsumi; T Yoshimori
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 2.  Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis.

Authors:  M J Clemens
Journal:  Prog Mol Subcell Biol       Date:  2001

Review 3.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

Authors:  J M Olefsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

4.  Inhibition of glucose and dehydroascorbic acid uptakes by resveratrol in human transformed myelocytic cells.

Authors:  J B Park
Journal:  J Nat Prod       Date:  2001-03       Impact factor: 4.050

Review 5.  The glucose-regulated proteins: stress induction and clinical applications.

Authors:  A S Lee
Journal:  Trends Biochem Sci       Date:  2001-08       Impact factor: 13.807

6.  Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response.

Authors:  Y Wang; J Shen; N Arenzana; W Tirasophon; R J Kaufman; R Prywes
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

7.  Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.

Authors:  J I Hisatake; T Ikezoe; M Carey; S Holden; S Tomoyasu; H P Koeffler
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

Review 8.  Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.

Authors:  Anupam Bishayee
Journal:  Cancer Prev Res (Phila)       Date:  2009-04-28

9.  AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.

Authors:  Carles Cantó; Zachary Gerhart-Hines; Jerome N Feige; Marie Lagouge; Lilia Noriega; Jill C Milne; Peter J Elliott; Pere Puigserver; Johan Auwerx
Journal:  Nature       Date:  2009-04-23       Impact factor: 49.962

10.  Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein.

Authors:  Shuo Wei; Hsiao-Ching Chuang; Wan-Chi Tsai; Hsiao-Ching Yang; Shiuh-Rong Ho; Andrew J Paterson; Samuel K Kulp; Ching-Shih Chen
Journal:  Mol Pharmacol       Date:  2009-04-16       Impact factor: 4.436

View more
  27 in total

1.  Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation.

Authors:  Michael J Powell; Mathew C Casimiro; Carlos Cordon-Cardo; Xiaohong He; Wen-Shuz Yeow; Chenguang Wang; Peter A McCue; Michael W McBurney; Richard G Pestell
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

2.  Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression.

Authors:  Chun-Han Chen; Po-Hsien Huang; Po-Chen Chu; Mei-Chuan Chen; Chih-Chien Chou; Dasheng Wang; Samuel K Kulp; Che-Ming Teng; Qianben Wang; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.

Authors:  Hsiang-Yu Lin; Yi-Chiu Kuo; Yu-I Weng; I-Lu Lai; Tim H-M Huang; Shuan-Pei Lin; Dau-Ming Niu; Ching-Shih Chen
Journal:  Prostate       Date:  2012-04-26       Impact factor: 4.104

Review 4.  Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2013-12-10

5.  Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity.

Authors:  Tamara P Kondratyuk; Eun-Jung Park; Laura E Marler; Soyoun Ahn; Yang Yuan; Yongsoo Choi; Rui Yu; Richard B van Breemen; Bin Sun; Juma Hoshino; Mark Cushman; Katherine C Jermihov; Andrew D Mesecar; Clinton J Grubbs; John M Pezzuto
Journal:  Mol Nutr Food Res       Date:  2011-06-29       Impact factor: 5.914

6.  Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.

Authors:  Kalpana Tilekar; Neha Upadhyay; Jessica D Hess; Lucasantiago Henze Macias; Piotr Mrowka; Renato J Aguilera; Franz-Josef Meyer-Almes; Cristina V Iancu; Jun-Yong Choe; C S Ramaa
Journal:  Eur J Med Chem       Date:  2020-07-02       Impact factor: 6.514

7.  Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.

Authors:  Arron Sikka; Manjinder Kaur; Chapla Agarwal; Gagan Deep; Rajesh Agarwal
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

8.  2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.

Authors:  Haibin Xi; Metin Kurtoglu; Huaping Liu; Medhi Wangpaichitr; Min You; Xiongfei Liu; Niramol Savaraj; Theodore J Lampidis
Journal:  Cancer Chemother Pharmacol       Date:  2010-07-01       Impact factor: 3.333

Review 9.  Regulation of pyruvate metabolism in metabolic-related diseases.

Authors:  Nam Ho Jeoung; Chris R Harris; Robert A Harris
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

10.  OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro.

Authors:  El-shaimaa A Arafa; Ahmed H Abdelazeem; Hany H Arab; Hany A Omar
Journal:  Acta Pharmacol Sin       Date:  2014-01-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.